This immunotherapy combination shrinks rare, neuroendocrine: Study - TheHealthSite
 

This immunotherapy combination shrinks rare, neuroendocrine: Study TheHealthSiteAccording to a new study, after using a combination of ipilimumab (6 weeks) and nivolumab (2 weeks) the results showed that 42 per cent of patients with the ...



أكثر...